Lakefront Biotherapeutics (LKFT)
28.61
+0.34
(+1.20%)
USD |
NASDAQ |
Jun 10, 16:00
28.60
-0.01
(-0.03%)
After-Hours: 20:00
Lakefront Biotherapeutics Enterprise Value : -1.543B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | -1.543B |
| June 09, 2026 | -1.566B |
| June 08, 2026 | -1.595B |
| June 05, 2026 | -1.582B |
| June 04, 2026 | -1.576B |
| June 03, 2026 | -1.616B |
| June 02, 2026 | -1.632B |
| June 01, 2026 | -1.614B |
| May 29, 2026 | -1.561B |
| May 28, 2026 | -1.563B |
| May 27, 2026 | -1.601B |
| May 26, 2026 | -1.605B |
| May 22, 2026 | -1.617B |
| May 21, 2026 | -1.599B |
| May 20, 2026 | -1.623B |
| May 19, 2026 | -1.675B |
| May 18, 2026 | -1.670B |
| May 15, 2026 | -1.646B |
| May 14, 2026 | -1.617B |
| May 13, 2026 | -1.574B |
| May 12, 2026 | -1.628B |
| May 11, 2026 | -1.620B |
| May 08, 2026 | -1.545B |
| May 07, 2026 | -1.601B |
| May 06, 2026 | -1.530B |
| Date | Value |
|---|---|
| May 05, 2026 | -1.558B |
| May 04, 2026 | -1.553B |
| May 01, 2026 | -1.584B |
| April 30, 2026 | -1.595B |
| April 29, 2026 | -1.593B |
| April 28, 2026 | -1.556B |
| April 27, 2026 | -1.553B |
| April 24, 2026 | -1.544B |
| April 23, 2026 | -1.539B |
| April 22, 2026 | -1.508B |
| April 21, 2026 | -1.524B |
| April 20, 2026 | -1.499B |
| April 17, 2026 | -1.499B |
| April 16, 2026 | -1.527B |
| April 15, 2026 | -1.507B |
| April 14, 2026 | -1.526B |
| April 13, 2026 | -1.547B |
| April 10, 2026 | -1.557B |
| April 09, 2026 | -1.547B |
| April 08, 2026 | -1.525B |
| April 07, 2026 | -1.522B |
| April 06, 2026 | -1.491B |
| April 02, 2026 | -1.490B |
| April 01, 2026 | -1.468B |
| March 31, 2026 | -1.452B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 163.15B |
| Karyopharm Therapeutics, Inc. | 345.40M |
| Ocugen, Inc. | 404.04M |
| Nkarta, Inc. | 19.95M |
| Zenas BioPharma, Inc. | 751.81M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 16.25M |
| Revenue (Quarterly) | 7.582M |
| Total Expenses (Quarterly) | -8.663M |
| EPS Diluted (Quarterly) | 0.2457 |
| Gross Profit Margin (Quarterly) | 25.95% |
| Earnings Yield | 30.26% |
| Operating Earnings Yield | 34.86% |
| Normalized Earnings Yield | 40.15 |